Xilis
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
801 Capitola Dr Ste 12, Durham, North Ca...Phone Number
(984) 377-6738Website
www.xilis.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Xilis
Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and supports drug discovery and development for pharmaceutical companies. Xilis' proprietary MicroOrganoSphere (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution. Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, the MOS technology is speeding up development and clinical trials of cancer drugs by enabling analysis of authentic tumor microenvironments, high-throughput preclinical modeling, and clinical patient selection capabilities.Explore more
Xilis Org Chart
CB
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xilis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Xilis is spiking on competitors!
Xilis, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Xilis
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Xilis has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Xilis launches new products
Check if Xilis has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Xilis recently announced quarterly report
Click to see if Xilis had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Xilis as Masked Content
Find more new buyers
Compare Similar Companies to Xilis
Compare insights from companies similar to Xilis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Xilis is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Xilis is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Xilis.
Xilis financials insights
Gather financial insights about Xilis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$3M
2022
Series A
$89M
Xilis Tech Stack
A closer look at the technologies used by Xilis
See more technologies
Most Recent Scoops
Open Position
Open Position
Hiring Plans
Xilis is hiring in Information Technology for the first time in 12 months.
Hiring Plans
Hiring Plans
Hiring Plans
Xilis News & Media
Xilis Announces Formation of its Scientific Advisory Board
Company developing breakthrough clinically-predictive patient tumor avatar platform with native tumor–immune biology to accelerate drug discovery and development and revolutionize patient care DURHAM, N.C. , Dec. 15, 2022 /PRNewswire/ -- Xilis, a pioneering biotech company advancing its...Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million
DURHAM, N.C.--(BUSINESS WIRE)--Series A extension will bring total round to $89M and enable Xilis to build its capabilities in supporting biopharma collaborations for drug discoveryXilis Announces Breast Cancer Oncologist Dr. Daniel F. Hayes to Join Clinical Advisory Board
DURHAM, N.C.--(BUSINESS WIRE)--Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. Hayes, MD, FACP, FASCO, has joined the company’s Clinical Advisory Board (CAB). Dr. Hayes is a Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology ProgramXilis Participates in €325MM Oncode-PACT Consortium to Accelerate the Development of Cancer Drugs
DURHAM, N.C.--(BUSINESS WIRE)--Xilis participates in Oncode-PACT, a consortium focused on developing new demonstrably effective cancer drugs faster and more cost-effectively
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Xilis
Sign Up For FreeTo access detailed company insights
Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and supports drug discovery and development for pharmaceutical companies. Xilis' proprietary MicroOrganoSphere (MOS) technology consists of mini... Read More
